Pharming reports positive Phase II results for leniolisib in genetic immune disorders

Racura Oncology receives approval for RC220 trial to proceed to higher dose

Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201

Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer

Sophos IRB and ALCMI partner to support lung cancer research

CSL and Alentis partner for lixudebart development and commercialisation for rare kidney and liver diseases

MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK

UTR Therapeutics' UTRxMYCN M1-14 receives US FDA Orphan Drug Designation and Rare Pediatric Disease Designation

AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations

QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance

Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC

Akeso enrols first patient in global Phase III trial of cadonilimab vs nivolumab in first-line gastric cancer

Astellas doses first patient in Phase 3 lung cancer study

AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment

Insmed's ARIKAYCE sNDA granted priority review by FDA